Clinical Trial

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Study acronym: PEMREC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 30, 2021 (before its estimated June 2022 completion). Its status may not reflect the trial's current state.
Summary
This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-09-26; most recent amendment 2021-09-29.
Status change: Not Yet Recruiting → Recruiting 2020-06-11
Trial Details
NCT Number NCT04109755
Lead Sponsor University Hospital, Geneva
Conditions Rectum Cancer, Rectal Cancer
Enrollment 25 participants
Start Date 2020-06-02
Primary Completion 2022-06 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2021-09-30